Venous thromboembolism in patients with cancer undergoing surgical exploration

被引:11
作者
Ruff, Samantha M. [1 ]
Weber, Kathryn T. [1 ]
Khader, Adam [1 ]
Conte, Charles [2 ]
Kadison, Alan [2 ]
Sullivan, James [2 ]
Wang, John [2 ]
Zaidi, Raza [2 ]
Deutsch, Gary B. [2 ]
机构
[1] Long Isl Jewish Med Ctr, Northwell Hlth, Dept Gen Surg, 270-05 76th Ave, Queens, NY 11040 USA
[2] Northwell Hlth, Div Surg Oncol, 450 Lakeville Rd, Lake Success, NY 11042 USA
关键词
Cancer; Deep vein thrombosis; Neoplasm; Surgery; Venous thromboembolism; Discharge; MAJOR ABDOMINAL-SURGERY; PANCREATIC-CANCER; RISK-FACTORS; PROPHYLAXIS; VTE; PREVENTION; DURATION; COAGULATION; MULTICENTER; THROMBOSIS;
D O I
10.1007/s11239-018-1774-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Malignancy and surgery are both independent risk factors for venous thromboembolism (VTE) events. The current NCCN guidelines recommend VTE prophylaxis for up to 28days after major abdominal or pelvic surgery for malignancy. We set out to evaluate the rate and timing of VTEs among patients with gastric, pancreatic, colorectal, and gynecologic malignancies who underwent surgery. We performed a retrospective review of the NSQIP database (2005-2013) focusing on patients with gastric, colorectal, pancreatic, and gynecologic malignancies. Our primary endpoint was a diagnosis of VTE within 30days of surgery. We analyzed 128,864 patients in this study. On multivariable analysis, patients with pre-operative sepsis (OR 2.36, CI 2.04-2.76, p<0.001), disseminated cancer (OR 1.73, CI 1.55-1.92, p<0.001), congestive heart failure (OR 1.69, CI 1.25-2.28, p=0.001), gastric cancer (OR 1.3, CI 1.09-1.56, p=0.004), and pancreatic cancer (OR 1.2, CI 1.03-1.30, p=0.021) were morelikely to have a VTE. Of patients who had a VTE event, 34% occurred after discharge from surgery (gastric: 25%, colorectal 34%, pancreatic 31%, gynecologic malignancy 42%). Our study demonstrates thatpatients who undergo an operation for malignancy with pre-operative sepsis, disseminated cancer, congestive heart failure, gastric cancer, or pancreatic cancer are more likely to develop a VTE within 30days of their operation. Of those patients who developed a VTE, approximately one-third occurred after discharge during a 30day post-operative period. This data supports that further studies are needed to determine the appropriate length of post-operative VTE chemoprophylaxis in patients with cancer.
引用
收藏
页码:316 / 323
页数:8
相关论文
共 38 条
[21]   Venous thromboembolism and prognosis in cancer [J].
Khorana, Alok A. .
THROMBOSIS RESEARCH, 2010, 125 (06) :490-493
[22]   Venous thromboembolism and cancer: Risks and outcomes [J].
Lee, AYY ;
Levine, MN .
CIRCULATION, 2003, 107 :I17-I21
[23]   American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer [J].
Lyman, Gary H. ;
Khorana, Alok A. ;
Falanga, Anna ;
Clarke-Pearson, Daniel ;
Flowers, Christopher ;
Jahanzeb, Mohammad ;
Kakkar, Ajay ;
Kuderer, Nicole M. ;
Levine, Mark N. ;
Liebman, Howard ;
Mendelson, David ;
Raskob, Gary ;
Somerfield, Mark R. ;
Liebman, Howard ;
Mendelson, David ;
Raskob, Gary ;
Somerfield, Mark R. ;
Thodiyil, Paul ;
Trent, David ;
Francis, Charles W. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (34) :5490-5505
[24]   Management of venous thromboembolism in cancer patients:: ESMO Clinical Recommendations [J].
Mandala, M. ;
Falanga, A. ;
Roila, F. .
ANNALS OF ONCOLOGY, 2008, 19 :126-127
[25]   Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients [J].
Mandala, M. ;
Reni, M. ;
Cascinu, S. ;
Barni, S. ;
Floriani, I. ;
Cereda, S. ;
Berardi, R. ;
Mosconi, S. ;
Torri, V. ;
Labianca, R. .
ANNALS OF ONCOLOGY, 2007, 18 (10) :1660-1665
[26]   Pulmonary embolism after major abdominal surgery in gynecologic oncology [J].
Martino, Martin A. ;
Borges, Elana ;
Williamson, Eva ;
Siegfried, Sylvia ;
Cantor, Alan B. ;
Lancaster, Johnathan ;
Roberts, William S. ;
Hoffman, Mitchel S. .
OBSTETRICS AND GYNECOLOGY, 2006, 107 (03) :666-671
[27]   Post-Discharge Venous Thromboembolism After Cancer Surgery Extending the Case for Extended Prophylaxis [J].
Merkow, Ryan P. ;
Bilimoria, Karl Y. ;
McCarter, Martin D. ;
Cohen, Mark E. ;
Barnett, Carlton C. ;
Raval, Mehul V. ;
Caprini, Joseph A. ;
Gordon, Howard S. ;
Ko, Clifford Y. ;
Bentrem, David J. .
ANNALS OF SURGERY, 2011, 254 (01) :131-137
[28]  
National Comprehensive Cancer Network, 2017, CANC ASS VEN THROMB
[29]   Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial [J].
Neoptolemos, John P. ;
Palmer, Daniel H. ;
Ghaneh, Paula ;
Psarelli, Eftychia E. ;
Valle, Juan W. ;
Halloran, Christopher M. ;
Faluyi, Olusola ;
O'Reilly, Derek A. ;
Cunningham, David ;
Wadsley, Jonathan ;
Darby, Suzanne ;
Meyer, Tim ;
Gillmore, Roopinder ;
Anthoney, Alan ;
Lind, Pehr ;
Glimelius, Bengt ;
Falk, Stephen ;
Izbicki, Jakob R. ;
Middleton, Gary William ;
Cummins, Sebastian ;
Ross, Paul J. ;
Wasan, Harpreet ;
McDonald, Alec ;
Crosby, Tom ;
Ma, Yuk Ting ;
Patel, Kinnari ;
Sherriff, David ;
Soomal, Rubin ;
Borg, David ;
Sothi, Sharmila ;
Hammel, Pascal ;
Hackert, Thilo ;
Jackson, Richard ;
Buechler, Markus W. .
LANCET, 2017, 389 (10073) :1011-1024
[30]   Pen operative venous thromboembolism prophylaxis in gynaecological cancer patients. A survey of current practice [J].
Petch, Sarah ;
Norris, Lucy ;
O'Toole, Sharon ;
Gleeson, Noreen ;
Abu Saadeh, Feras .
THROMBOSIS RESEARCH, 2016, 145 :126-128